KRAS and colorectal carcinoma: However, the initial objective response rate (ORR) of sotorasib in KRAS G12C-mutant CRC patients was only 7% (3 out of 42 patients) [20], while the preliminary response rate of adagrasib was 17% (3 out of 18 patients) [21].